Dr. Kim reports grants from the National Institutes of Health, personal fees from Bristol-Myers Squibb, and grants and personal ... Rao, MD, MHS, Deputy Editor, reports that she has stock holdings/options in Eli Lilly and Pfizer. Sankey V.
Annals of Internal Medicine · 6/29/2015
Merck's compensation committee said Frazier's incentive pay and stock awards could have been higher ... the company might point to Big Pharma rival (and Merck's sometime partner) Bristol-Myers Squibb ($BMY). The company suffered a 17% drop in net …
FiercePharma · ByTracy Staton · 4/22/2013
Bristol-Myers Squibb watched its stock climb 9% as investors rubbed their hands together on news that its key PD-1 checkpoint inhibitor Opdivo (nivolumab) turned in an impressive performance in patients with advanced squamous cell lung cancer. The …
Pharma Times · 10/31/2014
More from Bing News
Bristol Myers-Squibb and BASF. At both Allos Therapeutics and Bone Care International, Mr. Caruso worked closely with current Cellectar director Paul Berns, contributing significantly to those companies' successful growth, which led to acquisitions by ...
GlobeNewswire · 6/16/2015
Taylor was previously employed by and currently owns restricted stock in Bristol-Myers Squibb, and is a paid consultant or advisor for Aegerion, Ambrx, Calibrium, Genkyotex, Isis Pharmaceuticals, Nimbus Discovery, Yabao Pharmaceuticals, and Cadila …
MedPage Today · ByKristina Fiore · 12/18/2014
On Tuesday, Merck stock jumped as much as 5.9 percent after the company raised its profit forecast for the year, and finished the day up 5.04 percent at $59.98. Pfizer finished down 0.32 percent at $34.48. Bristol-Myers Squibb finished down 0.95 percent …
Philadelphia Daily News · 4/29/2015
Why would a person choose to buy Bristol-Myers' products or invest in its stock, rather than its competitors'? So that's what not to do. If you are in a situation where you must write a mission statement, I think you should try for something closer to a ...
Entrepreneur · 7/22/2013
Andrew N. Wilner, MD: Hello. I am Dr. Andrew Wilner, reporting from the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Copenhagen, Denmark. I am here today with Dr. Fred Lublin, Saunders …
Medscape News · 10/10/2013
She has already won several long-fought battles, currying widening support from shareholders ticked off over corporate scandals, exorbitant CEO pay and widespread stock losses ... Davis." Bristol-Myers Squibb's board is finally acquiescing to a longtime ... · ByGary Strauss · 4/27/2003
Is it already fully baked into stock prices? Conover: This is an important question ... is a particularly promising area for growth for pharmaceutical firms and that Bristol-Myers and Merck look like some of the best investment opportunities.
Morning Star · 4/29/2015

Bristol-Myers Squibb

Bristol-Myers Squibb, often referred to as BMS, is an American pharmaceutical company, headquartered in New York City. Bristol-M…
Bristol-Myers Squibb, often referred to as BMS, is an American pharmaceutical company, headquartered in New York City. Bristol-Myers Squibb manufactures prescription pharmaceuticals in several therapeutic areas, including cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders. Its mission is to "discover, develop and deliver innovative medicines that help patients prevail over serious diseases."
Data from: Wikipedia · Freebase